Skip to main content
United States

Clinical Studies

Clinical evidence i Stock 544966382

PFO closure has been extensively studied

There are several randomized controlled trials studying PFO closure devices, including the RESPECT trial for the Amplatzer PFO Occluder. These trials were designed and conducted to compare PFO closure to medical management to see if there was a greater benefit to patients to have their PFO closed to prevent another stroke.

Read on to learn more.

The RESPECT trial¹

Device Used: Amplatzer™ PFO Occluder

Number of patients: 980

Timeframe: Median 5.9 years follow-up

Key result: Lower rate of stroke recurrence with the Amplatzer PFO Occluder plus medication* than medication alone.

*Antithrombotic medication (antiplatelets or anticoagulants).

Read an overview of the study Read the published study

Amplatzer™ PFO Occluder and Amplatzer™ Talisman™ PFO Occluder post approval study (PFO PAS)

Abbott continues to collect data on our PFO closure devices. In fact, enrollment for a large study is currently underway. Talk to your doctor to find out if you are eligible to participate.

Devices Used: Amplatzer™ PFO Occluder and Amplatzer™ Talisman™ PFO Occluder

Number of patients needed: 1,214

Long-term follow up: 5 years after receiving the device.

Read more about this study

CLOSE trial²

The CLOSE Trial studied patent foramen ovale closure and compared it to antiplatelet medication alone and anticoagulation medication alone. This study was conducted in France and Germany and studied 663 recent cryptogenic stroke patients who had a PFO. Patients were split into three groups: PFO closure and antiplatelet medication, antiplatelet medication alone, or anticoagulation medication alone. Patients were followed for a median of 5.3 years. The study results showed that patients who had their PFO closed and took antiplatelet medication had a lower rate of stroke recurrence than patients who only took antiplatelet medication. There were not enough data to draw a conclusion between PFO closure and anticoagulation medication.

CLOSE - National Center for Biotechnology Information CLOSE - New England Journal of Medicine
  1. Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377:1022-32.
MAT-2002553 v4.0 | Item approved for U.S. use only.

Sign up for information on PFO and stroke.

If you or a loved one have a PFO and have experienced a stroke, we have resources you may find helpful.

Sign up Receive more information on reducing risk of another stroke REGISTER NOW